Orange Book product · Generic (ANDA)
ATAZANAVIR SULFATE
ATAZANAVIR SULFATE
At a glance
Feb 02, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 02, 2022
4 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
ATAZANAVIR SULFATE
Strength
EQ 150MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 212278
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ATAZANAVIR SULFATE
- 2014REYATAZBrand (NDA)
NDA 206352 · BRISTOL MYERS SQUIBB
- 2003REYATAZBrand (NDA)
NDA 021567 · BRISTOL MYERS SQUIBB
- 2021ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 212579 · LAURUS
- 2020ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 210575 · ZYDUS PHARMS
- 2020ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 209717 · AMNEAL
- 2018ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 208177 · MYLAN
- 2018ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 200626 · CIPLA
- 2018ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 204806 · AUROBINDO PHARMA
- 2014ATAZANAVIR SULFATEGeneric (ANDA)
ANDA 091673 · TEVA PHARMS USA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
